Related Experiment Videos
Design of enzyme inhibitors using iterative protein crystallographic analysis
K Appelt1, R J Bacquet, C A Bartlett
1Agouron Pharmaceuticals, Inc., La Jolla, California 92037.
Journal of Medicinal Chemistry
|July 1, 1991
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
In Vitro and In Vivo Activity of a Novel Catheter Lock Solution against Bacterial and Fungal Biofilms.
Antimicrobial agents and chemotherapy·2018
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2015
[Clinical experience in the diagnosis and treatment of kidney trauma].
Der Urologe. Ausg. A·2011
Discovery of TL10: A Soluble and Long-Acting MC4R Agonist with Tunable Lipidation for Sustained Pharmacological Activity.
Journal of medicinal chemistry·2026
Discovery and Optimization of Novel Nonhydroxamate LpxC Inhibitors for the Treatment of Multidrug-Resistant Gram-Negative Infections.
Journal of medicinal chemistry·2026
Fragment-Based Discovery of Potent RNA-Competitive Inhibitors of the DEAH-Box RNA Helicase DHX8.
Journal of medicinal chemistry·2026
Discovery and Optimization of a WRN Helicase Inhibitor Series through Structure-Guided Drug Design from a Covalent Fragment Binding Insight.
Journal of medicinal chemistry·2026
Novel Benzofuran Derivatives as SARM1 Inhibitors for Treating Axonal Degeneration.
ACS medicinal chemistry letters·2026
Novel Compounds as SMARCA2 Inhibitors for Treating Non-small Cell Lung Cancer.
ACS medicinal chemistry letters·2026
Structure-Activity Relationship Studies Resulting in the Identification of Potent and Selective Salt-Inducible Kinase Inhibitors.
ACS medicinal chemistry letters·2026
Structural Preferences and ADMET Regulation of Fluorinated Small-Molecule Drugs.
ACS medicinal chemistry letters·2026